Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Prostate-Specific Antigen"" wg kryterium: Temat


Tytuł:
Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Autorzy:
Rius Bilbao L; Department of Urology, Barrualde-Galdakao Integrated Health Organisation, Osakidetza Basque Health Service, Calle Itsasondo 10, 3B 48993, Getxo Bizkaia, Spain. .; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. .
Aguirre Larracoechea U; Research Unit, Barrualde-Galdakao Integrated Health Organisation, Osakidetza Basque Health Service, Galdakao, Spain.; Kronikgune Institute for Health Services Research, Barakaldo, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Galdakao, Spain.
Valladares Gomez C; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.; Department of Clinical Laboratory Medicine, Ezkerraldea-Enkarterri-Cruces Integrated Health Organisation, Osakidetza Basque Health Service, Barakaldo, Spain.
Remmers S; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Mar Medina C; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.; Department of Clinical Laboratory Medicine, Barrualde-Galdakao Integrated Health Organisation, Osakidetza Basque Health Service, Galdakao, Spain.
Pokaż więcej
Corporate Authors:
Phi Basque Study Group
Źródło:
World journal of urology [World J Urol] 2024 Mar 13; Vol. 42 (1), pp. 141. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/pathology
Male ; Humans ; Prospective Studies ; Neoplasm Grading ; Risk Assessment ; Biopsy ; Decision Making
Czasopismo naukowe
Tytuł:
Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
Autorzy:
Cui F; Department of Urology, Affiliated Taizhou Second People's Hospital of Yangzhou University , 225500, Taizhou, China.; Department of Urology, The Fourth Affiliated Hospital of Jiangsu University , 212002, Zhenjiang, China.
Qiu Y; Cancer Institute, The Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, 225500, Zhenjiang, Zhenjiang, China.
Xu W; Cancer Institute, The Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, 225500, Zhenjiang, Zhenjiang, China.
Zou C; Department of General Surgery, Suzhou Hospital, Affiliated Hospital of Medical School Nanjing University, No. 1 Lijiang Road, 215163, Suzhou, China. .
Fan Y; Cancer Institute, The Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, 225500, Zhenjiang, Zhenjiang, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Mar 06; Vol. 24 (1), pp. 305. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Systematic Review; Meta-Analysis; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/surgery
Male ; Humans ; Prostatectomy ; Consensus ; Databases, Factual
Czasopismo naukowe
Tytuł:
Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.
Autorzy:
Down L; Department of Health and Community Sciences, University of Exeter, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, UK. .
Barlow M; Department of Health and Community Sciences, University of Exeter, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Bailey SER; Department of Health and Community Sciences, University of Exeter, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Mounce LTA; Department of Health and Community Sciences, University of Exeter, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Merriel SWD; Centre for Primary Care & Health Services Research, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
Watson J; Centre for Academic Primary Care (CAPC), Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
Martins T; Department of Health and Community Sciences, University of Exeter, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Mar 01; Vol. 22 (1), pp. 82. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Male ; Humans ; Adult ; Middle Aged ; Cohort Studies ; Ethnicity ; Retrospective Studies ; Primary Health Care ; United Kingdom/epidemiology ; White
Czasopismo naukowe
Tytuł:
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Autorzy:
Roberts MJ; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Royal Brisbane and Women's Hospital, Herston, Qld, Australia.; Redcliffe Hospital, Redcliffe, Qld, Australia.; Faculty of Medicine, Centre for Clinical Research, The University of Queensland, Brisbane, Qld, Australia.
Conduit C; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.
Davis ID; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Department of Medical Oncology, Eastern Health, Box Hill, Vic., Australia.; Monash University Eastern Health Clinical School, Box Hill, Clayton, Vic., Australia.
Effeney RM; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Royal Brisbane and Women's Hospital, Herston, Qld, Australia.; Redcliffe Hospital, Redcliffe, Qld, Australia.
Williams S; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Martin JM; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, NSW, Australia.; University of Newcastle, Newcastle, NSW, Australia.
Hofman MS; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Centre, Melbourne, Vic., Australia.
Hruby G; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; University of Sydney, Sydney, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia.
Eapen R; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.; Olivia Newton-John Cancer Research Institute, Heidelberg, Vic., Australia.; Austin Hospital, Heidelberg, Vic., Australia.
Gianacas C; School of Population Health, UNSW Sydney, Sydney, NSW, Australia.; The George Institute for Global Health, Newtown, NSW, Australia.
Papa N; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic., Australia.
Lourenço RA; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.
Dhillon HM; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, NSW, Australia.
Allen R; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.
Fontela A; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.
Kaur B; The George Institute for Global Health, Newtown, NSW, Australia.
Emmett L; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Sydney, NSW, Australia.; University of NSW, Sydney, NSW, Australia.
Pokaż więcej
Corporate Authors:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Źródło:
BJU international [BJU Int] 2024 Feb; Vol. 133 Suppl 3, pp. 39-47. Date of Electronic Publication: 2023 Sep 14.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/radiotherapy
Prostatic Neoplasms*/surgery
Male ; Humans ; Prostate/pathology ; Positron Emission Tomography Computed Tomography/methods ; Androgen Antagonists/therapeutic use ; Neoplasm Recurrence, Local/pathology ; Australia/epidemiology ; Prostatectomy/methods ; Salvage Therapy/methods ; Gallium Radioisotopes/therapeutic use ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe
Tytuł:
Association between oxidative balance score and prostate specific antigen among older US adults.
Autorzy:
Li J; The National Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China.
Yang C; The National Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China.
Xiang K; The National Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China.
Pokaż więcej
Źródło:
Frontiers in public health [Front Public Health] 2024 Jan 22; Vol. 11, pp. 1336657. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Oxidative Stress*
Prostate-Specific Antigen*
Aged ; Humans ; Male ; Middle Aged ; Diet ; Nutrition Surveys ; Prospective Studies
Czasopismo naukowe
Tytuł:
Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men.
Autorzy:
Lee KM; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Bryant AK; Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Lynch JA; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Robison B; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Alba PR; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Agiri FY; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Pridgen KM; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
DuVall SL; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Yamoah K; Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.; James A. Haley Veterans' Hospital, Tampa, Florida, USA.
Garraway IP; Department of Surgical and Preoperative Care, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.; Department of Urology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Rose BS; VA San Diego Healthcare System, San Diego, California, USA.; Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Jan; Vol. 130 (2), pp. 224-231. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Prostatic Neoplasms*/pathology
Humans ; Male ; Black People ; Probability ; White People ; Early Detection of Cancer/methods ; Early Detection of Cancer/statistics & numerical data ; Mass Screening
Czasopismo naukowe
Tytuł:
Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Autorzy:
Ahlberg M; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. .
Garmo H; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, UK.
Stattin P; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Gedeborg R; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Edlund C; Urologkliniken, Hallands sjukhus, Kungsbacka, Sweden.
Holmberg L; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, UK; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Bill-Axelson A; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
Scandinavian journal of urology [Scand J Urol] 2024 Mar 14; Vol. 59, pp. 63-69. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/pathology
Male ; Humans ; Watchful Waiting ; Case-Control Studies ; Magnetic Resonance Imaging
Czasopismo naukowe
Tytuł:
Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Autorzy:
Carbonell E; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Mercader C; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. .
Sureda J; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Gutiérrez A; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Muñoz J; Department of Urology, Parc Taulí Hospital Universitari, Sabadell, Spain.
Gallardo E; Department of Medical Oncology, Parc Taulí Hospital Universitari, Sabadell, Spain.
Feltes N; Department of Radiation Oncology, Consorci Sanitari de Terrassa, Hospital de Terrassa, Terrassa, Spain.
Mases J; Department of Radiation Oncology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Valduvieco I; Department of Radiation Oncology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Vilaseca A; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Franco A; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Alcaraz A; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Musquera M; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Ribal MJ; Department of Urology, Hospital Clínic de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2024 Mar 13; Vol. 42 (1), pp. 133. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/surgery
Male ; Humans ; Prognosis ; Retrospective Studies ; Cryotherapy ; Salvage Therapy ; Neoplasm Recurrence, Local/therapy
Czasopismo naukowe
Tytuł:
Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.
Autorzy:
McLaughlin PW; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Department of Radiation Oncology, Assarian Cancer Center, Ascension Providence Hospital, Novi, MI, USA.
Cousins MM; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. .; Department of Advanced Radiation Oncology, Self Regional Healthcare, Greenwood, SC, USA. .
Tsodikov A; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Soni PD; Department of Radiation Oncology, Dignity Health Cancer Institute, Phoenix, AZ, USA.
Crook JM; British Columbia Cancer Agency and University of British Columbia, Kelowna, BC, Canada.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 09; Vol. 14 (1), pp. 5810. Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/epidemiology
Male ; Humans ; United States/epidemiology ; Incidence ; Early Detection of Cancer ; Mass Screening/methods
Czasopismo naukowe
Tytuł:
Normalised repeat serum prostate-specific antigen: associations with age and magnetic resonance imaging results.
Autorzy:
Dang H; Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. .
Huang V; Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Bratt O; Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Pokaż więcej
Źródło:
Scandinavian journal of urology [Scand J Urol] 2024 Mar 06; Vol. 59, pp. 54-57. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Magnetic Resonance Imaging*
Male ; Humans ; Odds Ratio ; Pelvis ; Prostate
Czasopismo naukowe
Tytuł:
Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
Autorzy:
Lee JN; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim MY; Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Kang JH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kang JK; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Chung JW; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Ha YS; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Choi SH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim BS; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim HT; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim TH; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Yoo ES; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim SH; Department of Radiology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kwon TG; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. .
Pokaż więcej
Źródło:
Investigative and clinical urology [Investig Clin Urol] 2024 Mar; Vol. 65 (2), pp. 132-138.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Prostatic Neoplasms, Castration-Resistant*/pathology
Male ; Humans ; Retrospective Studies ; Treatment Outcome ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Automated radiolabeling and handling of Ac-PSMA-617 using a robotic pipettor.
Autorzy:
Ahn SH; Molecular Cancer Imaging Facility, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA.
Belanger AP; Molecular Cancer Imaging Facility, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2024 Mar; Vol. 67 (3), pp. 111-115. Date of Electronic Publication: 2024 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
Radioisotopes*
Robotic Surgical Procedures*
Dipeptides*
Heterocyclic Compounds, 1-Ring*
Prostate-Specific Antigen*
Actinium ; Zirconium
Czasopismo naukowe
Tytuł:
Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer.
Autorzy:
Greenland NY; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Cowan JE; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Stohr BA; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Simko JP; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Carroll PR; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Chan E; Departments of Pathology and Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2024 Mar; Vol. 84 (4), pp. 614-623. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/pathology
Male ; Humans ; Neoplasm Grading ; Biopsy ; Prostate/pathology ; Prostatectomy/methods
Czasopismo naukowe
Tytuł:
Early response monitoring during [ Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
Autorzy:
Neubauer MC; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland. .
Nicolas GP; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
Bauman A; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
Fani M; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
Nitzsche E; Nuclear Medicine and PET-Center, Cantonal Hospital Aarau, Aarau, Switzerland.
Afshar-Oromieh A; Nuclear Medicine, University Hospital Bern, Bern, Switzerland.
Forrer F; Nuclear Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Rentsch C; Urology, University Hospital Basel, Basel, Switzerland.
Stenner F; Oncology, University Hospital Basel, Basel, Switzerland.
Templeton A; Oncology, St. Claraspital, Basel, Switzerland.
Schäfer N; Nuclear Medicine, University Hospital Lausanne, Lausanne, Switzerland.
Wild D; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
Chirindel A; Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4051, Basel, Switzerland.
Pokaż więcej
Corporate Authors:
all investigators on behalf of the SSNM Therapy Working Group
Źródło:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Mar; Vol. 51 (4), pp. 1185-1193. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms, Castration-Resistant*/diagnostic imaging
Prostatic Neoplasms, Castration-Resistant*/radiotherapy
Prostatic Neoplasms, Castration-Resistant*/drug therapy
Urea/*analogs & derivatives
Male ; Humans ; Switzerland ; Single Photon Emission Computed Tomography Computed Tomography ; Treatment Outcome ; Heterocyclic Compounds, 1-Ring/therapeutic use ; Lutetium/therapeutic use ; Dipeptides/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Autorzy:
Ravi P; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kwak L; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Devlies W; Department of Urology, KU Leuven, Leuven, Belgium.
Xie W; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Chipidza F; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Yang X; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bubley G; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Kaplan I; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Kibel AS; Department of Urology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Nguyen P; Department of Radiation Oncology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Taplin ME; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
The Prostate [Prostate] 2024 Mar; Vol. 84 (4), pp. 342-348. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/pathology
Male ; Humans ; Prostate/pathology ; Neoadjuvant Therapy ; Radiotherapy, Adjuvant ; Margins of Excision ; Prostatectomy ; Adjuvants, Pharmaceutic ; Salvage Therapy ; Neoplasm Recurrence, Local/surgery ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
Autorzy:
Davik P; Department of Urology, St Olavs Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Remmers S; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Elschot M; Department of Radiology and Nuclear Medicine, St Olavs Hospital, Trondheim, Norway.; Department of Circulation and Medical Imaging (ISB), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Roobol MJ; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Bathen TF; Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.; Department of Radiology and Nuclear Medicine, St Olavs Hospital, Trondheim, Norway.
Bertilsson H; Department of Urology, St Olavs Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2024 Mar; Vol. 133 (3), pp. 278-288. Date of Electronic Publication: 2023 Sep 12.
Typ publikacji:
Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/pathology
Male ; Humans ; Aged ; Retrospective Studies ; Magnetic Resonance Imaging/methods ; Prostate/diagnostic imaging ; Prostate/pathology
Czasopismo naukowe
Tytuł:
New Molecular Markers for Prostate Cancer Diagnosis.
Autorzy:
Amiri M; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. .
Asadi Samani L; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. .
Kashi AH; Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University, Tehran, Iran. .
Khadem N; Department of Cardiovascular, Faculty of Medicine, Urmia University of Medical Science, Urmia, Iran. .
Ziaee SAM; Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University, Tehran, Iran. .
Mowla SJ; Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. .
Pokaż więcej
Źródło:
Urology journal [Urol J] 2024 Feb 28; Vol. 21 (1), pp. 1-13. Date of Electronic Publication: 2024 Feb 28.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/pathology
Male ; Humans ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/urine ; Antigens, Neoplasm/genetics ; Antigens, Neoplasm/urine ; RNA
Czasopismo naukowe
Tytuł:
[ Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
Autorzy:
Rosar F; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Burgard C; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Larsen E; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Khreish F; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Marlowe RJ; Spencer-Fontayne Corporation, Jersey City, NJ, USA.
Schaefer-Schuler A; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Maus S; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Petto S; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Bartholomä M; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
Ezziddin S; Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. .
Pokaż więcej
Źródło:
Cancer imaging : the official publication of the International Cancer Imaging Society [Cancer Imaging] 2024 Feb 22; Vol. 24 (1), pp. 27. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Positron Emission Tomography Computed Tomography*/methods
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/pathology
Dipeptides*
Heterocyclic Compounds, 1-Ring*
Prostate-Specific Antigen*
Male ; Humans ; Gallium Radioisotopes ; Retrospective Studies ; Neoplasm Recurrence, Local/diagnostic imaging ; Oligopeptides ; Edetic Acid
Czasopismo naukowe
Tytuł:
[ Tc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
Autorzy:
Li B; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Ding X; Department of Biomedical Informatics, Columbia University Graduate School of Arts and Sciences, New York, NY, United States.
Duan L; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Shi J; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Tang M; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Zhang J; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Zhao Z; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Wu X; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Gao Y; Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Pokaż więcej
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Feb 20; Vol. 15, pp. 1326858. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/surgery
Male ; Humans ; Retrospective Studies ; Lymphatic Metastasis/diagnostic imaging ; Single Photon Emission Computed Tomography Computed Tomography
Czasopismo naukowe
Tytuł:
Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post-operative outcomes.
Autorzy:
Giesen A; Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Van den Broeck T; Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Develtere D; Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Raskin Y; Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.; Department of Urology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Wymer K; Department of Urology, Mayo Clinic, Rochester, MN, USA.
Eden C; Department of Urology, Royal Surrey County Hospital, Guildford, UK.
Claessens M; Department of Urology, AZ Klina, Brasschaat, Belgium.
Hente R; Department of Urology, AZ Klina, Brasschaat, Belgium.
Rans K; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Berghen C; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
De Meerleer G; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Langley S; Department of Urology, Royal Surrey County Hospital, Guildford, UK.
Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA.
Heidenreich A; Department of Urology, University Hospital Cologne, Cologne, Germany.
Pfister D; Department of Urology, University Hospital Cologne, Cologne, Germany.
Joniau S; Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. .; Department of Urology, AZ Klina, Brasschaat, Belgium. .
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2024 Feb 15; Vol. 42 (1), pp. 81. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Prostate-Specific Antigen*
Prostatic Neoplasms*/surgery
Male ; Humans ; Prostate ; Pelvis ; Seminal Vesicles
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies